- Home
- CRSP vs RIOT Comparison
CRSP vs RIOT Comparison
Compare CRSP & RIOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- RIOT
- Stock Information
- Founded
- CRSP 2013
- RIOT 2000
- Country
- CRSP Switzerland
- RIOT United States
- Employees
- CRSP N/A
- RIOT N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- RIOT Retail: Computer Software & Peripheral Equipment
- Sector
- CRSP Health Care
- RIOT Technology
- Exchange
- CRSP Nasdaq
- RIOT Nasdaq
- Market Cap
- CRSP 3.3B
- RIOT 2.8B
- IPO Year
- CRSP 2016
- RIOT N/A
- Fundamental
- Price
- CRSP $36.29
- RIOT $8.07
- Analyst Decision
- CRSP Buy
- RIOT Strong Buy
- Analyst Count
- CRSP 16
- RIOT 11
- Target Price
- CRSP $73.07
- RIOT $16.25
- AVG Volume (30 Days)
- CRSP 2.1M
- RIOT 31.6M
- Earning Date
- CRSP 05-06-2025
- RIOT 07-30-2025
- Dividend Yield
- CRSP N/A
- RIOT N/A
- EPS Growth
- CRSP N/A
- RIOT N/A
- EPS
- CRSP N/A
- RIOT N/A
- Revenue
- CRSP $37,675,000.00
- RIOT $458,749,000.00
- Revenue This Year
- CRSP $26.79
- RIOT $73.00
- Revenue Next Year
- CRSP $297.32
- RIOT $11.58
- P/E Ratio
- CRSP N/A
- RIOT N/A
- Revenue Growth
- CRSP N/A
- RIOT 59.99
- 52 Week Low
- CRSP $30.04
- RIOT $6.19
- 52 Week High
- CRSP $67.88
- RIOT $15.87
- Technical
- Relative Strength Index (RSI)
- CRSP 46.12
- RIOT 46.42
- Support Level
- CRSP $35.38
- RIOT $8.47
- Resistance Level
- CRSP $38.13
- RIOT $9.20
- Average True Range (ATR)
- CRSP 1.73
- RIOT 0.49
- MACD
- CRSP -0.03
- RIOT -0.10
- Stochastic Oscillator
- CRSP 26.30
- RIOT 8.81
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About RIOT Riot Platforms Inc.
Riot Platforms Inc is a vertically integrated Bitcoin mining company focused on building, supporting, and operating blockchain technologies. The company's segments include Bitcoin Mining and Engineering. The Bitcoin Mining segment generates revenue from the Bitcoin the Company earns through its Bitcoin Mining activities. The Engineering segment generates revenue through customer contracts for custom engineered electrical products. It generates the majority of its revenue from the Bitcoin Mining segment.